NCT03784599 - T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 18, 2018

Primary Completion Date

May 17, 2021

Study Completion Date

May 17, 2021

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Trastuzumab emtansine

Infusion

DRUG

Osimertinib

Tablet

Trial Locations (5)

Maastricht UMC+, Maastricht

VU medical center, Amsterdam

Antoni van Leeuwenhoek ziekenhuis - Netherlands Cancer Institute, Amsterdam

Erasmus MC, Rotterdam

Univercity Medical Center Groningen, Groningen